46 results about "Diuretic" patented technology

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

The present technology is generally directed to flow cartridges configured to measure and / or detect analytes in urine. A representative flow cartridge includes a urine inlet configured to receive urine from a patient, a flow channel fluidly coupled to the urine inlet, and sensors fluidly coupled to the flow channel that are configured to measure parameters of the urine flow. The sensors are aligned with corresponding sensing zones of the flow channel and are operable to generate sensor data based on urine flow through the sensing zones. In some embodiment, the sensor data is used to provide fluid therapy to the patient by adjusting an amount or rate of diuretic and / or hydration fluid based on the sensor data.

The present invention features methods and compositions for the intranasal, sublingual, and subcutaneous administration of bumetanide for the treatment of subjects suffering from edema refractory to oral diuretics.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker, wherein the dose of each component is below the lowest dose approved for the treatment of hypertension for the component.

The invention relates to a pet composition for preventing urinary tract calculi and improving urinary tract health and application thereof. The composition for pets comprises a mucosal barrier repairing agent, an antibacterial adhesive, an inflammation regulator, a diuretic and an antioxidant, the antibacterial adhesive comprises a combination of D-mannose and a cranberry extract. The composition for pets provided by the invention can be used for repairing bladder mucosa from multiple dimensions, inhibiting bacteria from adhering to the bladder wall, reducing urinary stones, regulating inflammation and improving urinary tract health.

This present disclosure relates to fluid therapy based on adjusted urine output rate and / or sodium output rate, and associated systems, devices, and methods. Exemplary methods can include receiving a sodium excretion input for the patient; receiving a urine output rate; determining an adjusted urine output rate based on the sodium excretion input and the urine output rate; and providing fluid therapy based on the adjusted urine output rate. By determining the amount and / or rate of the infused diuretic and / or hydration fluid based on a patient's actual sodium excretion levels, embodiments of the present technology can optimize and / or customize all or a subset of a diuretic therapy to an individual patient's physiology.

This article provides a pharmaceutical composition for the treatment of hypertension, comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

This invention discloses a traditional Chinese medicine composition for assisting in the improvement of hand-foot-mouth disease in infants and young children, belonging to the field of traditional Chinese medicine technology. The composition consists of eight medicinal herbs: lotus leaf, coix seed, angelica dahurica, kudzu root, platycodon root, agastache rugosa, cimicifuga rhizome, and dandelion, with a defined optimal medicinal ratio. Based on the seasonal differences in the pathogenesis of hand-foot-mouth disease, this invention targets the core pathologies of winter (cold congestion of microvessels, water and sodium retention, and internal heat generation) and spring and summer (hypothalamic sympathetic activation, increased heart rate, and visceral heat overload). It also addresses the technical deficiencies of clinical Western medicine, cold-natured traditional Chinese medicine, calamine lotion, and diuretics, such as vasoconstriction, kidney damage, central nervous system disorders, increased skin exudation, and rebound water retention. This invention employs a combination of warming and cooling herbs, regulating the ascending and descending functions, and promoting diuresis and protecting the body's vital energy. The synergistic effects of these herbs can dilate spasmodic microvessels, improve renal perfusion, stabilize abnormal heart rates, stabilize the hypothalamic center, and assist in antagonizing enteroviruses. By targeting and reducing abnormal permeability of skin capillaries with Angelica dahurica and Platycodon grandiflorus, it reduces blood extravasation and inhibits the formation and exudation of herpes from the root cause. This invention has mild medicinal properties, is suitable for all seasons, and has high safety. It can effectively improve symptoms of hand-foot-mouth disease such as fever, herpes, irritability, and cold extremities, reduce the risk of severe illness, antagonize the toxic side effects of commonly used clinical drugs, and is suitable for the delicate constitution of infants and young children, possessing good prospects for clinical application and promotion.

Methods for controlling fluid management for a patient are disclosed herein. An example computer-implemented method comprises: initializing a fuzzy machine learning model based on a fluid management ruleset for a population including the patient; training the fuzzy machine learning model on historical medical data associated with the population to generate a trained fuzzy ruleset, the historical medical data including a plurality of indications of historical fluid management treatments for the population and associated treatment outcomes; receiving clinical data for the patient; generating a fluid management recommendation by applying the trained fuzzy ruleset to the clinical data for the patient; presenting, via a graphical user interface, the fluid management recommendation and one or more indications of corresponding rales included in the trained fuzzy ruleset to a clinician.

This present disclosure relates to fluid therapy based on adjusted urine output rate and / or sodium output rate, and associated systems, devices, and methods. Exemplary methods can include receiving a sodium excretion input for the patient; receiving a urine output rate; determining an adjusted urine output rate based on the sodium excretion input and the urine output rate; and providing fluid therapy based on the adjusted urine output rate. By determining the amount and / or rate of the infused diuretic and / or hydration fluid based on a patient's actual sodium excretion levels, embodiments of the present technology can optimize and / or customize all or a subset of a diuretic therapy to an individual patient's physiology.

Disclosed herein are novel methods and compositions for treating MD and / or endolymphatic hydrops. The composition comprises ebselen and optionally one or more a glutathione peroxidase (GPx) modulator or mimic compounds and'or one or more prescription diuretic compounds. Also disclosed are methods of increasing GPx activity and reducing free radical species and cochlear or vestibular inflammation in a subject.

The present application provides a system for determining a dosage of a diuretic required by a subject suffering from or at risk of heart failure, which facilitates a “closed loop” of measuring urinary parameters and treating. The system comprises at least a sodium measurement sensor, such as a chemo-electrical sensor, for measuring urinary sodium levels, and one or more processors, configured to receive the measured urinary sodium levels; calculate a subject-optimized dosage of the diuretic based on the measured urinary sodium levels, optionally using a machine learning algorithm; and provide an output comprising the calculated subject-optimized dosage of diuretic. The present application further comprises methods of using the system.

Materials and methods for treating hypertension (including resistant hypertension) with a combination of an M-atrial natriuretic peptide (MANP) and a diuretic agent (e.g., furosemide) are described herein.

Embodiments of the present technology can manage a patient's fluid removal based on one or more of the patient's urination, urinary conductivity, urinary sodium concentration, and / or urinary oxygen content. For example, in some embodiments, the patient's urinary sodium concentration (and / or an indication thereof, including, for example, the patient's urinary conductivity) can be compared to one or more urinary sodium concentration thresholds (e.g., a high urinary sodium concentration threshold and / or a low urinary sodium concentration threshold) to determine one or more adjustments to the patient's therapy, such as, for example, diuretic administration rate, hydration fluid infusion rate, hydration fluid compatibility percentage, etc. Additionally or alternatively, the patient's urinary oxygen content can be compared to one or more urinary oxygen content thresholds (e.g., a high urinary oxygen content threshold and / or a low urinary oxygen content threshold) to determine one or more adjustments to the patient's therapy.

A apparatus and method to treat patients with acute decompensated heart failure (ADHF), heart failure or another fluid overload condition, that includes: administrating a diuretic to the patient to increase urine output of the patient; monitoring a rate or amount of urine output by the patient after administration of the diuretic; infusing a hydration liquid into the patient to induce an increase in the urine output; and adjusting the rate or amount of the hydration liquid infused into the patient to achieve a target fluid loss in the patient.

This invention provides a method of treating hypertension in a hypertensive subject, the method administering to the subject, an amount of a diuretic and an amount of a CYP 11β2 beta hydroxylase inhibitor once or twice per day, wherein the amounts taken together are sufficient to treat hypertension in the hypertensive subject when taken in combination with other antihypertensive agents. In particular, the method is sufficient to elicit a safe and robust reduction in hypertension (>10 mmHg reduction in systolic blood pressure) in the hypertensive subject.

To provide management of fluid levels in a patient and associated devices, systems and methods.SOLUTION: Devices, systems, and methods for delivering fluid therapy to a patient are disclosed herein. An exemplary method can comprise the steps of: obtaining a urine output rate from a patient; causing a diuretic to be provided to the patient at a dosage rate, where the dosage rate is increased over a period of time such that the urine output rate increases to be above a predetermined threshold within the period of time; and causing a hydration fluid to be provided to the patient at a hydration rate. The hydration rate can be set based on the urine output rate to drive net fluid loss from the patient.SELECTED DRAWING: Figure 1

The invention relates to the technical field of traditional Chinese medicine preparations, and particularly discloses a traditional Chinese medicine preparation for treating heart failure and diuretic resistance and a preparation method of the traditional Chinese medicine preparation. The active extract is prepared from the following raw material medicines: astragalus membranaceus, ginseng, cinnamon, salvia miltiorrhiza, red paeony root, radix rehmanniae recen, cassia twig, ligusticum wallichii and pseudo-ginseng. On the basis of a traditional qi-tonifying and blood-activating treatment method, a treatment method for enhancing the effect of dredging collaterals and the effect of nourishing yin is combined, the cinnamon serves as a core monarch drug to warm and tonify yang of the heart and the kidney, and compatibility is scientific; the cortex cinnamomi is used for completely replacing radix aconiti lateralis preparata, so that potential cardiotoxicity and neurotoxicity risks caused by aconitum alkaloids are fundamentally eliminated; the traditional Chinese medicine preparation disclosed by the invention provides a solid guarantee for long-term and safe medication of patients with heart failure, is more suitable for treating intractable and complicated heart failure, and has a good clinical application value.

The present invention relates to the field of traditional Chinese medicine technology. A composition for inhibiting renal sodium reabsorption, its preparation method, and use are provided. The composition comprises the following raw materials in parts by weight: 10-12 parts of Evodia rutaecarpa, 12-16 parts of Achyranthes bidentata, 4-8 parts of Curcuma aromatica, 4-8 parts of Akebia, 8-12 parts of Glycyrrhiza uralensis, 5-7 parts of Juncus effusus, 1-3 parts of cinnamaldehyde, and 0.5-1.5 parts of folic acid. The composition is specifically designed for people with high-salt diets, has a wide variety of raw material sources, and a simple preparation process. It can overcome the limitations and toxic side effects of existing diuretics.

The present invention relates to an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment that binds to adrenomedullin, for use in congestion therapy in a patient with congestive hypertension; heart failure, in particular acute heart failure; wherein said anti-ADM antibody or anti-ADM fragment binds to the N-terminal portion (aa 1 to 21) of adrenomedullin YRWSMNNFWGLRSFGCRFGTC (SEA ID NO. 22), and wherein said patient is resistant to diuretics or does not respond to diuretic therapy.

A pharmaceutical composition comprising a diuretic and at least one additional active ingredient selected from the group consisting of ACE inhibitors, sartans, calcium channel blockers, alpha blockers, and beta blockers, wherein the diuretic is in a first pharmaceutical form that increases its dissolving rate. The invention also relates to the above composition for use in the treatment of a condition selected from heart failure, arterial hypertension, myocardial fibrosis, and cardiac hypertrophy.

The invention discloses a new application of a sodium-glucose cotransporter 2 inhibitor in preparation of drugs for treatment and / or adjuvant treatment of ascites due to cirrhosis. The sodium-glucose cotransporter 2 inhibitor disclosed by the invention can take effect together with furosemide, effectively increases urine sodium and urine excretion of intractable or intractable ascites due to cirrhosis caused by diuretic resistance, improves the uncomfortable symptoms of abdominal distension of the patients, reduces the total amount of ascites, and is good in treatment effect and free of toxic and side effects. The treatment dilemma that the ascites of the patients cannot be effectively reduced by medicines in the prior art is effectively solved.

Provided are a computer program, an information processing device, and an information processing method. 　The computer program makes a computer execute a processing that includes: evaluating the body water storage state in a patient having heart failure or renal dysfunction; determining whether or not the taking of a diuretic drug should be recommended on the basis of a result of the evaluation; and notifying a terminal device for the patient about a proposal relating to the taking of the diuretic drug on the basis of a result of the determination.

The present invention relates to the technical field of biomedicine, and in particular to a sulfonamide compound for therapeutic use, an enantiomer thereof, a preparation method, and uses. The present invention provides the following beneficial effects: the provided sulfonamide compound and the enantiomer thereof have the characteristics of high stability, a prolonged duration of action, superior efficacy, and the like, thereby serving as a superior diuretic and a novel anti-cerebral edema drug.

A method to treat patients suffering from fluid overload including: administrating a diuretic to the patient to increase urine output of the patient; monitoring intravascular volume of the patient; and maintaining the patient in a condition in which the intravascular volume is below a baseline intravascular volume and above a hemodynamic level by adjusting the administered diuretic.